Aquestive Therapeutics, Inc. (AQST) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

11/25

Growth 3 Margin 1 Expansion 3 Platform 1 Financial 3

latest quarter score

Earnings Reports

11
AQST Q2 2026: 38% Revenue Growth Supports Epinephrine Market Expansion and Launch Readiness
August 12, 2026
9
Aquestive Therapeutics (AQST) Q1 2026: 66% Revenue Jump Driven by Royalty Windfall and Debt Refi Runway
May 14, 2026
9
AQST Q4 2025: 50% Salesforce Expansion Signals Aggressive Anafilm Launch Readiness
March 05, 2026
9
Aquestive Therapeutics (AQST) Q3 2025: $160M Capital Secured to Fund Anafilm Launch and Pipeline Acceleration
November 06, 2025
9
Aquestive Therapeutics (AQST) Q2 2025: Pre-Launch Spend Rises $4.2M as Anafilm Nears FDA Decision
August 12, 2025
5
Aquestive Therapeutics (AQST) Q1 2025: $8.7M Revenue Drop Highlights Anafilm Launch Bet
July 06, 2025
Aquestive Therapeutics (AQST) Q4 2024: Anaphylm NDA Filing Initiates Path to 2026 Launch Amid Commercial and Clinical Expansion
March 06, 2025
AQST Q3 2024: R&D Spend Up 66% as Anafilm and AQST-108 Pipeline Advance
November 05, 2024
Aquestive Therapeutics (AQST) Q2 2024: Revenue Up 52% on Deferred Recognition, Anafilm Nears NDA Milestone
August 07, 2024
AQST Q1 2024: $77.5M Raise Extends Runway, Accelerates Anafilm and Libervant Commercial Prep
May 08, 2024
Aquestive Therapeutics (AQST) Q4 2023: Royalty Revenue Jumps 104% as Oral Rescue Pipeline Nears Pivotal Milestones
March 06, 2024
17
AQST Q3 2023: Revenue Jumps 42% as Debt Recast Extends Runway for Anafilm Launch
November 07, 2023
Aquestive Therapeutics (AQST) Q2 2023: License and Royalty Revenue Jumps 168% as Epinephrine Pipeline Advances
August 07, 2023
Aquestive Therapeutics (AQST) Q1 2023: Non-Dilutive Capital Surges $22M as Debt Falls 18%
May 03, 2023
Aquestive Therapeutics (AQST) Q4 2022: Non-Dilutive Capital Surges Past $45M, Pivotal Epinephrine Study on Deck
March 08, 2023

Browse all companies